{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"OCEAN Trial: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation","description":" The OCEAN Trial found that rivaroxaban did not significantly reduce the incidence of stroke, systemic embolism, or new covert embolic events compared with aspirin in patients at&amp;nbsp;high risk&amp;nbsp;for stroke who had undergone catheter ablation for atrial fibrillation&amp;nbsp;(AFib)&amp;nbsp;at least one year earlier. The central question\u2014whether patients with a successful AFib ablation can safely&amp;nbsp;discontinue&amp;nbsp;anticoagulation\u2014remains&amp;nbsp;unresolved. Overall, the trial reinforces the importance of individualized risk assessment rather than routine discontinuation of anticoagulation after ablation.&amp;nbsp;   In this interview,&amp;nbsp;Thomas F. Deering MD, FACC&amp;nbsp;and&amp;nbsp;Atul&amp;nbsp;Verma, MD FACC&amp;nbsp;discuss&amp;nbsp;the&amp;nbsp;\u201cOCEAN Trial: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation\u201d.&amp;nbsp;  ","author_name":"ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research","author_url":"http:\/\/accelaccorg.libsyn.com\/website","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/40203495\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/198880300"}